Astellas/Vical CMV vaccine ASP0113 fails stem cell transplant trial

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the international Phase III HELIOS trial

Read the full 271 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE